Two basal and one HER2-E human breast cancers harboured outlier EGFR expression (Fig. 6b), suggesting EGFR remains a potential therapeutic target in a subset of breast cancers that has yet to be fully realized clinically. Here, ERBB2 is linked to breast cancer.